Citigroup Inc Mei Pharma, Inc. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.41 - $8.8 $2,519 - $54,067	-6,144 Reduced 99.98%	1 $0
Q2 2022 Aug 10, 2022	SELL	$0.42 - $0.65 $4,768 - $7,380	-11,354 Reduced 64.88%	6,145 $4,000
Q1 2022 May 12, 2022	SELL	$0.54 - $2.74 $5,739 - $29,123	-10,629 Reduced 37.79%	17,499 $11,000
Q4 2021 Feb 10, 2022	BUY	$2.33 - $3.37 $35,297 - $51,052	15,149 Added 116.72%	28,128 $75,000
Q3 2021 Nov 10, 2021	BUY	$2.52 - $2.99 $32,707 - $38,807	12,979 New	12,979 $36,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $385M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.